OncoMatch/Clinical Trials/NCT07206498
A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
Is NCT07206498 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Osimertinib (Tagrisso®) and WSD0922-FU for non small cell lung cancer (nsclc).
Treatment: Osimertinib (Tagrisso®) · WSD0922-FU — This is a Phase I/II, Open Label Study of WSD0922-FU in Combination with Osimertinib for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose disease has progressed with third-generation EGFR-TKI with C797S mutation or is newly diagnosed with CNS metastasis with EGFR Del19 or L858R mutation
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR sensitive mutation
Patients who have been genetically tested to carry EGFR sensitive mutations
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Received chemotherapy...within 4 weeks before the first administration of the study drug
Cannot have received: radiotherapy
Received radiotherapy...within 4 weeks before the first administration of the study drug
Cannot have received: biological therapy
Received biological therapy...within 4 weeks before the first administration of the study drug
Cannot have received: targeted therapy
Received targeted therapy...within 4 weeks before the first administration of the study drug
Cannot have received: endocrine therapy
Received endocrine therapy...within 4 weeks before the first administration of the study drug
Cannot have received: immunotherapy
Received immunotherapy...within 4 weeks before the first administration of the study drug
Cannot have received: anti-tumor drug treatments
Received...other anti-tumor drug treatments within 4 weeks before the first administration of the study drug
Cannot have received: EGFR tyrosine kinase inhibitor
Exception: more than two EGFR-TKI inhibitors for part A
Have previously received more than two EGFR-TKI inhibitors for part A
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07206498 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, radiotherapy, biological therapy disqualifies patients from enrollment.
Does this trial require EGFR?
Yes, EGFR sensitive mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify